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Purpose: Sedatives and analgesics are commonly used in mechanically ventilated patients in 
the intensive care unit. Sedation guidelines have been shown to improve sedation management 
as well as various patient outcomes. The main objective was to evaluate adherence to a sedation 
guideline with both sedative prescribing and documentation of Richmond Agitation-Sedation 
Scale (RASS) scores.
Methods: In a retrospective chart review, data was collected on 111 medical intensive care 
unit patients mechanically ventilated via endotracheal tube for 12 hours or greater at Brigham 
and Women’s Hospital. Fifty-seven patients were evaluated pre-guideline implementation and 
54 patients were evaluated post-guideline.
Results: Significant increases were seen in the post-guideline group in goal-directed seda-
tion with a patient-specific RASS goal in the sedation order: 21.3 vs 85.4% (P , 0.001), and 
mean number of sedation assessments per 24 hours using the RASS: 4.7 vs 11.4 (P , 0.001). 
  Similarly, this group experienced a higher percentage of RASS scores at their sedation goal: 
31.4 vs 44.1% (P , 0.001). No difference was seen in other clinical endpoints.
Conclusion: Implementation and routine application of a hospital pain and sedation guideline 
was associated with significantly improved sedation metrics, such as goal-directed sedation, as 
well as frequency of sedation level assessment and documentation. An increase was observed 
in the time that post-guideline patients spent at or near their RASS goal.
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Introduction
Mechanically ventilated patients often receive both analgesic and sedative medica-
tions to reduce agitation, alleviate discomfort and pain, increase ventilator synchrony, 
decrease oxygen consumption, and ensure patient safety.1,2 The etiology of agitation 
in mechanically ventilated intensive care unit (ICU) patients can be linked to pain, 
delirium, sleep deprivation, alarms, tests and procedures, prolonged immobility, 
and other comorbidities.1,2 Sedatives and analgesics have adverse effects associated 
with them including oversedation, respiratory depression, hemodynamic instability, 
  gastrointestinal effects, and drug accumulation.1–3 Utilization of sedatives and anal-
gesics in the ICU has been associated with increased risk of delirium, duration of 
mechanical ventilation, ICU length of stay, and cost.1–12
Current guidelines for sedation and analgesia recommend titration of sedatives to 
a goal using a validated assessment tool to improve the quality of sedation therapy 
in the ICU.1,13 Despite demonstration of both the feasibility and benefits of imple-
menting   sedation assessment tools and guidelines,14–26 recent surveys indicate only Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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about 60%–70% of institutions have a sedation guideline 
in place.27–29
In 2006, a guideline for the management of pain, 
sedation, and neuromuscular blockade was developed 
and implemented at Brigham and Women’s Hospital. The 
Richmond Agitation-Sedation Scale (RASS), a 10-point, 
validated sedation scale, is the preferred sedation assess-
ment tool recommended in the guideline.30,31 The objective 
of this retrospective analysis was to assess adherence with 
core guideline measures, including goal-directed sedation 
prescribing and sedation assessment using the RASS, and 
its association with patient outcomes.
Patients and methods
We conducted a retrospective analysis of patients receiv-
ing mechanical ventilation in the 20-bed medical intensive 
care unit (MICU) at Brigham and Women’s Hospital from 
February to March 2006 (pre-guideline) and February to 
March 2007 (post-guideline). Approval was obtained from 
the Institutional Review Board before study initiation. All 
patients $18 years old who were mechanically ventilated 
for $12 hours during the two 2-month periods were assessed 
for inclusion in the analysis. Patients were excluded if they 
were mechanically ventilated for ,12 hours or were receiv-
ing mechanical ventilation via a tracheostomy on admission 
to the ICU. Patients that received a tracheostomy during the 
study period were only followed until the procedure.
Baseline characteristics, including past medical his-
tory, vital signs over the first 24 hours of mechanical 
ventilation, critical labs, incidence of organ dysfunc-
tion, vasopressor requirement, and respiratory support 
were collected. Severity of illness of each patient group 
was estimated by the numbers of organ dysfunction in 
both groups. Organ dysfunction was defined using the 
following criteria: hematologic (platelet count , 80,000/
mm3), respiratory (PaO2/FiO2 , 300), renal (crea-
tinine $ 1.5 mg/dL), cardiovascular (average heart 
rate . 100 bpm over first 24 hours or necessity of vasoactive 
agents), and hepatic (Tbili $ 1.2 mg/dL). Critical medica-
tions were defined as continuous infusions of midazolam, 
lorazepam, propofol, dexmedetomidine, fentanyl, hydro-
morphone, insulin, and vasoactive agents.
Guideline information
In 2006, a multidisciplinary team of physicians, nurses, 
and pharmacists developed and implemented a 20-page 
hospital-wide guideline for the management of pain, agita-
tion, and neuromuscular blockade at our institution. The 
guideline provides core recommendations regarding medi-
cation selection and dosing, assessment of pain, sedation, 
delirium, paralysis, and use of daily interruption strategies. 
The guideline was implemented hospital-wide with education 
provided to all ICU nurses, physicians, and pharmacists at 
baseline. Educational sessions were provided every month 
to new physicians rotating through the ICU. Continuous 
education was also provided to ICU nurses and reinforced 
through annual competency training.
The guideline provides recommendations on assessment 
tools for sedation, analgesia, and neuromuscular blockade. 
Patients are assessed for pain using a numerical and/or visual 
analog scale if possible, and then for other etiologies of 
  agitation. Sedation should be assessed, via the RASS score, 
and documented at least once every 2 hours while patients are 
mechanically ventilated. The guideline recommends a goal 
RASS score of “0 to −1” for most patients, although specific 
exceptions exist (ie, neuromuscular blockade).
The guideline also provides education and recommen-
dations on drug administration and dosing for sedatives, 
analgesics, and antipsychotic agents. As per the guideline, 
nurses are able to administer and titrate analgesics and seda-
tives by either boluses or, if necessary, continuous infusions 
to the patient’s goal RASS score. Recommended sedatives 
include midazolam, propofol, lorazepam, diazepam, and 
dexmedetomidine. Propofol is the first-line agent in patients 
who meet criteria for head injury or frequent awakening 
for neurological assessment. Midazolam is considered 
first-line for patients who do not meet these criteria, with 
propofol, lorazepam, diazepam, and dexmedetomidine being 
second- and third-line agents. Recommended analgesics 
include fentanyl, morphine, and hydromorphone. Fentanyl 
is the preferred analgesic, especially in hemodynamically 
unstable patients, with hydromorphone and morphine 
being second-line   therapies. Use of bolus dosing is recom-
mended for select analgesics and sedatives before initiation 
and upward titration of continuous infusions.   Recommended 
antipsychotics include haloperidol, quetiapine, and 
  olanzapine. Incorporation of daily interruption strategies is 
recommended in patients not meeting exclusion criteria set 
forth by the guideline.
Simultaneously with guideline implementation, a change 
was implemented within the computerized provider order 
entry (CPOE) system. A field containing, “titrate to RASS = ” 
was programmed to auto-populate in all orders for continu-
ous sedation. Providers were able to enter a patient-specific 
RASS goal within the sedation order but could also leave 
this blank if they did not wish to specify a goal.Journal of Pain Research 2011:4
Table 1 Baseline demographics
Variable Pre-guideline 
n = 57
Post-guideline 
n = 54
P-value
Age, mean ± sD, years 63.3 ± 17.2 62.3 ± 16.5 0.83
Male, no. (%) 25 (43.9) 26 (48.1) 0.65
MAP, mean ± sD, mm hg 82.6 ± 12.7 75.4 ± 12.8 0.004
no. of vasoactive medications on admission per 
patient, mean ± sD
0.39 ± 0.7 0.76 ± 1 0.031
Patients with $2 vasoactive agents, no. (%) 3 (5.3) 12 (22.2) 0.009
no. organ dysfunction per patient, mean ± sD 1.8 ± 0.9 2.2 ± 1.1 0.037
Patients with $3 organ dysfunction, no. (%) 13 (22.8) 24 (44.4) 0.016
Organ dysfunction, no. (%)
  cardiac 33 (57.9) 39 (72.2) 0.11
  hematologic 3 (5.3) 8 (14.8) 0.09
  hepatic 12 (21.1) 15 (27.8) 0.41
  Renal 26 (45.6) 26 (48.1) 0.79
  Respiratory 30 (52.6) 33 (61.1) 0.56
scr, mean ± sD, mg/dL 2.0 ± 2.1 2.5 ± 2.7 0.29
WBc, mean ± sD, ×103/microliter 12.9 ± 6.2 13.5 ± 8.3 0.67
PMh, no. (%)
  DM 9 (15.8) 12 (22.2) 0.39
  cOPD/Asthma 18 (31.6) 12 (22.2) 0.27
  hypertension 23 (40.4) 14 (25.9) 0.11
  cAD 13 (22.8) 16 (29.6) 0.63
  chF/cardiomyopathy 13 (22.8) 5 (9.3) 0.05
  Atrial fibrillation 9 (15.8) 10 (18.5) 0.58
  cRi/esRD 11 (19.3) 10 (18.5) 0.71
  cancer 14 (24.6) 17 (31.5) 0.65
Abbreviations: CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; CRI, chronic renal insufficiency; DM, diabetes 
mellitus; esRD, end stage renal disease; PMh, past medical history.
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endpoints
The two primary endpoints were the frequency of docu-
mentation of a RASS goal in orders for continuous infu-
sions of sedatives as well as the frequency of assessment 
and documentation of patients’ RASS scores by the nurses. 
Secondary endpoints included time that the patient spent 
at or within one point of their RASS goal, time to initial 
RASS documentation, ICU and hospital length of stay, hos-
pital mortality duration of mechanical ventilation, amount 
of sedatives and analgesics administered, and number of 
tracheostomies, reintubations, and head computerized 
tomography or magnetic resonance imaging scans while 
patients were in the ICU.
statistical analyses
Discrete data are presented as the number and percent-
age of the occurrence of the variable. Continuous data are 
presented as means ± standard deviation (SD) for normally 
  distributed variables, and medians for non-normally distrib-
uted   variables. The Mantel Haenszel Chi Square test was 
used to compare categorical data between groups. The two-
Sided t-test was used to compare continuous parametric data 
while the Mann–Whitney U-test was used for nonparametric 
data. All statistical tests were two-tailed and used a cutoff of 
α , 0.05 for statistical significance.
Results
One hundred eighty-one patients receiving mechanical 
ventilation from February to March 2006 and February to 
March 2007 were screened. Seventy were excluded (49 due 
to   intubation ,12 hour, 20 were receiving   mechanical 
  ventilation via tracheostomy, and one due to transfer to 
surgical ICU within 18 hours of admission). Therefore, 
111 (66%) were included in the retrospective analysis: 
57 patients in the pre-guideline group and 54 patients in 
the post-guideline group. Baseline demographics (Table 1) 
were significantly different between the two groups with 
higher mean vasoactive agent requirements (0.39 vs 0.76; 
P = 0.03), mean organ dysfunctions (1.8 vs 2.2; P = 0.04), 
percentage of patients requiring two or more vasoactive 
agents (5.3% vs 22.2%; P = 0.009), percentage of patients 
with three or more organ dysfunctions (22.8% vs 44.4%; 
P = 0.02), and lower MAP (82.6 vs 75.4 mmHg; P = 0.004) 
in the post-guideline group.Journal of Pain Research 2011:4
4.7
11.4
0
2
4
6
8
10
12
RASS scores/24 hour sedation
RASS assessment documentation
Pre-guideline Post-guideline
P < 0.001
M
e
a
n
 
n
u
m
b
e
r
 
o
f
 
d
o
c
u
m
e
n
t
a
t
i
o
n
s
Figure 1 RAss assessments.
Abbreviation: RAss, Richmond Agitation-sedation scale.
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Primary endpoints
Primary outcomes are presented in Table 2. There were 
89 orders for continuous sedation in each group. In terms 
of continuous analgesia, there were 57 orders in the 
pre-guideline group and 65 orders in the post-guideline 
group. A significant increase was seen post-guideline in 
the   percentage of sedatives (21.3% vs 85.4%; P , 0.001) 
and analgesics (15.8 vs 55.4%; P , 0.001) ordered with a 
RASS goal. The total   number of RASS assessments docu-
mented while patients were sedated was higher in the post-
guideline group (Table 2). A significant difference favoring 
the post-guideline group was seen in the average number of 
RASS assessments per 24-hour period of sedation (Figure 1). 
The median number of daily RASS assessments per patient 
(Figure 2) was significantly higher for the majority of days 
in the post-guideline group.
secondary endpoints
In patients in the post-guideline group, those with a prespeci-
fied RASS goal experienced an increase in the percentage of 
RASS scores at goal (31.3% vs 44.1%; P , 0.001) and the 
number of scores within one point of goal (45.1% vs 66.7%; 
P , 0.001) (Figure 3). Fifty-four percent (54%) of sedation 
orders had a RASS goal of 0 to −1 while only 5% of orders 
had a RASS goal deeper than −2. Time to initial RASS 
assessment and documentation in the post-guideline group 
was significantly shorter (24.5 hours vs 2.4 hours; P , 0.001) 
in the post-guideline group.
Our study was not powered to detect differences in our 
secondary outcome parameters and, accordingly, no differ-
ence was seen between the pre- and post-guideline groups 
in mean ICU or hospital length of stay hospital mortality, 
duration of mechanical ventilation, number of reintubations, 
or number of head CT scans or MRIs performed after the 
initial 48 hours in the ICU. Midazolam (75% vs 78% patients; 
P = 0.96) and fentanyl (77% vs 81%; P = 0.60) were the most 
frequently prescribed sedative and analgesic in both the 
pre- and post-guideline groups, respectively. No difference 
was seen between the duration and amount of continuous 
analgesia and sedation among the two cohorts.
Discussion
In our retrospective cohort analysis, we found the implementa-
tion of a hospital-wide guideline for the management of pain, 
agitation, and neuromuscular blockade increased utilization 
of goal-directed administration of sedatives and frequency of 
sedation assessment documentation in a mechanically venti-
lated medical ICU population. Post-guideline improvements 
in sedation metrics were also demonstrated by faster time to 
initial sedation assessment and a higher percentage of RASS 
assessments at goal or within one point of goal.
Current sedation and analgesia guidelines recommend 
the use of sedation guidelines or protocols as well as titra-
tion of sedative dose to a defined endpoint.1 No guideline or 
protocol has been established as superior in the literature, and 
adaptation of other institutional protocols or guidelines can be 
  difficult. Clinicians seeking to improve sedation therapy 
should develop and implement local guidelines or protocols 
that fit the culture, resources, and medication formulary of 
their institution.32 Our study constitutes a quality improvement 
project to assess the impact of a local guideline on sedation 
Table 2 sedation metrics
Variable Pre-guideline 
n = 57
Post-guideline 
n = 54
P-value
no. of continuous intravenous sedation orders 89 89 0.69
sedation orders with RAss goal, no. (%) 19 (21.3) 76 (85.4) ,0.001
Total nr of RAss scores during sedation 1078 2762 0.002
no. of RAss per 24 hour sedation, mean ± sD 4.7 ± 4.9 11.4 ± 2.9 ,0.001
RAss scores at goal, % 31.4 44.1 ,0.001
RAss scores within 1 of goal, % 45.1 66.7 ,0.001
Time to initial RAss documentation, mean ± sD, hour 24.5 ± 39.1 2.4 ± 5.5 ,0.001
Abbreviation: RAss, Richmond Agitation-sedation scale.Journal of Pain Research 2011:4
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Figure 2 RAss Assessments.
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therapy in a mechanically ventilated medical intensive care 
unit population. Continuous quality assessment is needed to 
ensure adherence to guidelines or protocols, and to develop 
initiatives to improve adherence and outcomes.17,18 Analysis 
of metrics are needed to assess the impact of   guideline and 
protocolized care, however establishment of ideal sedation 
metrics is not defined in the literature.33 Published sedation 
improvement initiatives provide an array of sedation metrics 
used to validate the impact of the intervention on patient 
outcomes.17,24,33 In our analysis, the percentage of RASS 
assessments at (44%) or near goal (67%) was significantly 
higher post-guideline. This percentage is lower than reports 
from recent studies, however it should be noted that larger 
target sedation ranges were used.34,35
Several analyses are published in the literature examining 
the effects of different sedation related practices on outcomes 
in mechanically ventilated ICU patient populations.14–26 In 
1999, Brook and colleagues randomized 321 mechanically 
ventilated medical ICU patients to receive sedation by 
either a nursing-implemented protocol or by a non-protocol 
approach.14 The protocol allowed for nurses to administer and 
titrate analgesics and sedatives by either boluses or   continuous 
infusions to a pre-determined Ramsay score.   Protocolized 
patients experienced a shorter duration of mechanical ven-
tilation (89.1 vs 124 hours; P = 0.003), decreased ICU and 
hospital length of stay (5.7 vs 7.5 days; P = 0.013, and 14.0 
vs 19.9 days; P , 0.001, respectively), and a lower require-
ment for tracheostomy (6.2% vs 13.2%; P = 0.038). Patients 
getting non-protocol directed sedation had an increased 
duration of continuous infusion sedative therapy (3.5 
vs 5.6 days; P = 0.003), whereas protocol-directed sedation 
was determined to be an independent variable associated with 
successful weaning from mechanical ventilation (RR 1.37; 
P = 0.026). Brook and colleagues demonstrated clinically 
significant reductions in many clinical outcomes, but did 
not comprehensively evaluate the impact of sedation related 
metrics on their findings.14
In 2006, Chanques and colleagues conducted a 
before–after study to examine the impact of systematic 
assessment of pain and agitation in 230 surgical and medical 
ICU patients.19 Patients were assessed twice daily for pain 
using the numerical rating scale (NRS) or behavioral pain 
scale (BPS), and for sedation using the RASS. The post 
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Figure 3 sedation outcomes.
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intervention group demonstrated more RASS assessments 
per patient per day (1.3 vs 1.6; P , 0.001), fewer incidence 
of both pain and agitation (63% vs 42%; P = 0.002, and 
29% vs 12%; P = 0.002, respectively), reduced incidence of 
nosocomial infection (8% vs 17%; P = 0.01), and reduced 
duration of mechanical ventilation (120 vs 65 hours; 
P = 0.01). Despite a minimal increase in the frequency of 
sedation assessment, Chanques and colleagues described a 
lower incidence of several clinical outcomes. The optimal 
frequency of   sedation assessment has yet to be determined 
in the literature and current guidelines do not provide 
recommendations.1,17,33 Our guideline recommends seda-
tion assessments every 2 hours. More frequent assessment 
of RASS in our post-guideline cohort did not demonstrate 
improvement in clinical outcomes; however differences in 
sample size, sedative agent choices, and severity of illness 
amongst our cohort groups likely prevented us from seeing 
the differences demonstrated by Brook and colleagues and 
Chanques and colleagues.
Analysis of sedation improvement initiatives have shown 
various benefits and positive associations, such as decreased 
time of mechanical ventilation, time in the ICU, incidence 
of pain and agitation, incidence of nosocomial infections, 
amount of sedatives and analgesics administered, cost, and 
increased sedation assessments.14–26 Despite improvements 
in various sedation metrics, implementation of the guideline 
was not associated with improvement in clinical outcomes 
such as mortality, length of stay, and duration of mechanical 
ventilation. While improvement in clinical outcomes is ideal, 
our study was underpowered to detect these and should be 
viewed as a sedation metrics assessment.
Our study has several limitations that may have inhibited 
our ability to assess metrics and outcomes of guideline imple-
mentation in our cohort. First, our study was not prospective 
or randomized; however the analysis was performed using a 
sequential study of two time periods in which all consecutive 
patients were screened for enrollment. Second, due to retro-
spective design, documentation, and information availability, 
we were unable to evaluate cost considerations and incidence 
of nosocomial infections. Also, differences in the number of 
vasopressors and organ dysfunctions at baseline suggest our 
post-guideline group had a higher severity of illness. These 
significant differences may have resulted in our inability to 
detect improvement in clinical outcomes in the post-guideline 
cohort. Finally, in addition to the implementation of a seda-
tion guideline, a CPOE intervention was made for providers 
to enter a patient-specific RASS goal. This intervention did 
not require providers to enter a RASS goal, but may have 
contributed to the increase in patient-specific RASS goals 
seen in the sedative orders.
Conclusions
The implementation of a guideline for the management of 
pain and sedation was associated with increased utilization of 
goal-directed administration of sedatives, frequency of seda-
tion assessment documentation, and percentage of assess-
ments at or near goal in a mechanically ventilated medical 
ICU population; however these changes were not associated 
with improvement in clinical outcomes. The results could be 
attributable to differences in the severity of illness between 
the cohorts and sample size needed to evaluate specific 
outcome variables. Further analysis is needed to evaluate 
sedation guideline interventions and metrics that correlate 
with improvement in clinical outcomes.
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Fentanyl Hemodynamically compromised?
Yes
No
Choose from
Fentanyl
Morphine
Hydromorphone
Goal RASS
Score 0 to −1
Yes
No
Neuro/Head injury/need for frequent or 
rapid awakening or requiring Propofol
Choose from
Midazolam
Lorazepam
Consider Delirium
Yes
Choose from
Vecuronium 
Cisatracurium 
Pancuronium
Sedation-Agitation Management 
Goal: RASS 0 to −1, BIS Goal 60–80
Neuromuscular blockade management 
Is paralysis indicated in this patient? 
Is patient at goal RASS −4 to −5 and BIS Goal 40–60
Choose from
Haloperidol 
Olanzapine
Quetiapine
R
E
A
S
S
E
S
S
F
R
E
Q
U
E
N
T
L
Y
No
Patient on mechanical ventilation with continuous cardiopulmonary monitoring
Refer to Drug Fact Sheets for details 
Consider: renal failure, liver failure, heart failure, hypovolemic shock, Addison’s disease, and
hypothyroidism
Appendix 1 sedation guideline.
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